REGN Financial Facts

Income tax benefit: -101.08M
Total expenses: 857.32M
See Full Income Statement

Common Stock: 2K
Marketable securities: 488.03M
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 8/5/22 *Est. EPS Growth Rate +16.2% *Last Qtr.
Average EPS % Beat Rate +39.0% Revenue Growth Rate +17.4% *Last Qtr.
Average % Move 1-Wk after EPS -1.8% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/4/22 Q122 $11.49$10.04 +$1.45$2.97B$2.73B N/A Details
2/4/22 Q421 $23.72$18.37 +$5.35$4.95B$4.42B N/A Details
11/4/21 Q321 $15.37$9.22 +$6.15$3.45B$2.76B N/A Details
8/5/21 Q221 $25.80$17.69 +$8.11$5.14B$3.89B N/A Details
5/6/21 Q121 $9.89$9.00 +$0.89$2.53B$2.55B N/A Details
2/5/21 Q420 $9.53$8.43 +$1.10$2.42B$2.42B N/A Details
11/5/20 Q320 $8.36$7.13 +$1.23$2.29B$2.09B N/A Details
8/5/20 Q220 $7.16$5.98 +$1.18$1.95B$1.74B N/A Details